The authors of the abstract are
"It is now evident to everyone that we have taken the first step towards building a health economical file for NEX-20 for the treatment of multiple myeloma", says
© Modular Finance, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.606 SEK | -5.31% | -8.46% | -50.73% |
Apr. 16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
Mar. 08 | Transcript : Nanexa AB - Special Call |
The authors of the abstract are
"It is now evident to everyone that we have taken the first step towards building a health economical file for NEX-20 for the treatment of multiple myeloma", says
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
-50.73% | 7.5M | |
-10.84% | 187M | |
-59.36% | 82M |